Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,356,102
  • Shares Outstanding, K 111,982
  • Annual Sales, $ 605,220 K
  • Annual Income, $ -168,630 K
  • EBIT $ -177 M
  • EBITDA $ -191 M
  • 60-Month Beta 0.83
  • Price/Sales 2.18
  • Price/Cash Flow N/A
  • Price/Book 3.87

Options Overview Details

View History
  • Implied Volatility 71.92% (+0.69%)
  • Historical Volatility 56.45%
  • IV Percentile 85%
  • IV Rank 46.07%
  • IV High 99.94% on 10/22/25
  • IV Low 47.98% on 01/27/25
  • Expected Move (DTE 13) 0.94 (7.79%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 550
  • Volume Avg (30-Day) 536
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 35,938
  • Open Int (30-Day) 34,502
  • Expected Range 11.17 to 13.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.39
  • Number of Estimates 4
  • High Estimate -0.31
  • Low Estimate -0.50
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +36.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.70 +13.18%
on 11/07/25
12.89 -6.05%
on 11/28/25
+0.50 (+4.31%)
since 11/05/25
3-Month
10.70 +13.18%
on 11/07/25
14.77 -17.98%
on 10/06/25
-0.17 (-1.38%)
since 09/05/25
52-Week
10.70 +13.18%
on 11/07/25
34.13 -64.52%
on 12/18/24
-14.49 (-54.47%)
since 12/05/24

Most Recent Stories

More News
Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley...

NVCR : 12.11 (+2.98%)
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the 37 th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle,...

NVCR : 12.11 (+2.98%)
Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer,...

NVCR : 12.11 (+2.98%)
NovoCure: Q3 Earnings Snapshot

NovoCure: Q3 Earnings Snapshot

NVCR : 12.11 (+2.98%)
Novocure Reports Third Quarter 2025 Financial Results

Quarterly net revenues of $167 million, up 8% year-over-year, with 4,416 active patients on therapy as of September 30, 2025 Premarket approval application for Tumor...

NVCR : 12.11 (+2.98%)
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague,...

NVCR : 12.11 (+2.98%)
Wedbush Remains a Hold on NovoCure (NVCR)

Wedbush analyst David Nierengarten maintained a Hold rating on NovoCure today and set a price target of $18.00. The company’s shares closed last Friday at $13.49.Elevate Your Investing Strategy: Take...

NVCR : 12.11 (+2.98%)
Evercore ISI Sticks to Their Buy Rating for NovoCure (NVCR)

Evercore ISI analyst Vijay Kumar maintained a Buy rating on NovoCure today and set a price target of $25.00. The company’s shares opened today at $14.50.Elevate Your Investing Strategy: Take advantage...

NVCR : 12.11 (+2.98%)
Novocure to Report Third Quarter 2025 Financial Results

Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and...

NVCR : 12.11 (+2.98%)
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields therapy and best supportive care following stereotactic...

NVCR : 12.11 (+2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 12.77
2nd Resistance Point 12.49
1st Resistance Point 12.30
Last Price 12.11
1st Support Level 11.83
2nd Support Level 11.55
3rd Support Level 11.36

See More

52-Week High 34.13
Fibonacci 61.8% 25.18
Fibonacci 50% 22.42
Fibonacci 38.2% 19.65
Last Price 12.11
52-Week Low 10.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar